Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
MindMed Closes on Upsized Financing of $13.2m
MindMed has issued 24.95 million units at a unit price of CAD$0.53.
Champignon Appoints Dr. Bill Wilkerson to Board of Directors
Champignon Brands' new Director has extensive mental health credentials.
What A Trip! Psychedelics Stocks Flying High
Several psychedelics stocks have delivered impressive returns for investors in recent weeks.
Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer
Wood will lead research partnerships and the design of the Numinus patient-focused model.
Numinous Wellness to Commence Trading May 20th, Symbol “NUMI”
A new psychedelics company is to begin trading on May 20th on Canada's TSX Venture Exchange.
Champignon Appoints Pat McCutcheon To Board Of Directors
Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce the appointment of Pat McCutcheon to its board of directors effective immediately.
MindMed Announces Increase in Bought Deal Offering to Approximately $11.5 Million
Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase 21,699,000 units of the Company (the “Units”), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $0.53 (the “Issue Price”) for gross proceeds of $11,500,470 (the “Offering”).
NeonMind and Translational Life Sciences To Design Psilocybin Mushroom Clinical Trials
The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (FE:YG3) announces its majority owned subsidiary NeonMind has entered into an agreement entitled “CLINICAL TRIALS START-UP STUDY AGREEMENT” with Translational Life Sciences Inc. (“TLS”) to initiate clinical trials to test certain potential therapeutic effects of psilocybin and other compounds in psychedelic mushrooms.
- 1
